Aurobindo Pharma stock hit a 52-week high at ₹1,585, and quoted close to its record high of ₹1,592 hit in September 2024. HDFC Securities maintains 'Add' rating on the stock.

An FDA inspection of an Aurobindo Pharma manufacturing facility last fall noted more than half a dozen concerns, but at the time the drugmaker indicated they should all be quickly fixable. Now that ...

The FDA slapped Aurobindo Pharma, an Indian drugmaker, with a warning letter for failing to adequately investigate batch failures of active pharmaceutical ingredients and not evaluating the possible ...

Nov 5 (Reuters) - Indian drugmaker Aurobindo Pharma (ARBN.NS), opens new tab reported a 3.8% rise in profit on Wednesday, helped by steady domestic demand, especially for its anti-retroviral drugs for ...

Aurobindo Pharma Share Buyback, Aurobindo Pharma Buyback Price:Aurobindo Pharma on Monday (April 6) has announced a share buyback programme. Subject to required approvals from regulatory and/or ...